Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for Cynthia D. Robinson�
2.71
-0.11 (-3.90%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.66 - 2.94
52 week 1.25 - 5.19
Open 2.83
Vol / Avg. 3.85M/4.27M
Mkt cap 378.15M
P/E     -
Div/yield     -
EPS -0.71
Shares 139.54M
Beta 2.12
Inst. own 83%
May 21, 2014
Zogenix, Inc. Annual Shareholder Meeting - 8:30AM EDT - Add to calendar
May 5, 2014
Q1 2014 Zogenix, Inc. Earnings Release (Estimated) Add to calendar
Mar 5, 2014
Q4 2013 Zogenix, Inc. Earnings Conference Call - Webcast
Mar 5, 2014
Q4 2013 Zogenix, Inc. Earnings Release
Feb 12, 2014
Zogenix, Inc. at Leerink Swann Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -359.00% -244.93%
Operating margin -146.29% -161.13%
EBITD margin - -153.00%
Return on average assets -170.94% -83.71%
Return on average equity -6297.35% -491.54%
Employees 114 -
CDP Score - -

Address

Suite 650, 12400 High Bluff Drive
SAN DIEGO, CA 92130
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company�s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Director
Age: 54
Bio & Compensation  - Reuters
Roger L. Hawley Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
R. Scott Shively Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Cynthia Y. Robinson Ph.D. Chief Development Officer
Age: 54
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 48
Bio & Compensation  - Reuters